Nicotine patch + MK-4334 + Placebo patch + Placebo capsule
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cognitive Impairment Associated With Schizophrenia
Conditions
Cognitive Impairment Associated With Schizophrenia
Trial Timeline
Apr 27, 2022 → Nov 4, 2022
NCT ID
NCT05136690About Nicotine patch + MK-4334 + Placebo patch + Placebo capsule
Nicotine patch + MK-4334 + Placebo patch + Placebo capsule is a phase 1 stage product being developed by Merck for Cognitive Impairment Associated With Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT05136690. Target conditions include Cognitive Impairment Associated With Schizophrenia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05136690 | Phase 1 | Completed |
Competing Products
20 competing products in Cognitive Impairment Associated With Schizophrenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aricept (donepezil hydrochloride) + placebo | Eisai | Approved | 85 |
| Donepezil | Eisai | Approved | 85 |
| Aricept | Eisai | Phase 2 | 52 |
| Donanemab + Aducanumab | Eli Lilly | Phase 3 | 77 |
| ABT-126 + Placebo | AbbVie | Phase 2 | 52 |
| SDI-118 + Placebo | AbbVie | Phase 1 | 33 |
| ABT-288 Low Dose + Placebo + ABT-288 High Dose | AbbVie | Phase 2 | 52 |
| AZD5213 + AZD5213 + AZD5213 | AstraZeneca | Phase 2 | 52 |
| MK-8931 | Merck | Phase 1 | 33 |
| Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2) | Merck | Phase 3 | 77 |
| Rivastigmine | Novartis | Phase 3 | 77 |
| Rivastigmine | Novartis | Approved | 85 |
| Exelon (rivastigmine) + Placebo | Novartis | Approved | 85 |
| Canakinumab | Novartis | Phase 2 | 52 |
| Eviplera | Gilead Sciences | Approved | 84 |
| atorvastatin | Pfizer | Pre-clinical | 22 |
| bosutinib | Pfizer | Phase 1 | 32 |
| Aducanumab + Placebo | Biogen | Phase 2 | 49 |
| BIIB080 + BIIB080-matching placebo | Biogen | Phase 2 | 49 |
| BIIB104 | Biogen | Phase 2 | 49 |